HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.
HGC019 is a mRNA and Self-amplifying mRNA (saRNA) based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.
== Clinical trials == The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI), to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18–70) years.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).